Alliqua BioMedical is a New York-based biomedical products company that specializes in the development and manufacturing of electron-beam cross-linked hydrogels for the original equipment manufacturer market. Their hydrogel platform allows for the production of sheet gels with or without active ingredients, making it possible to effectively deliver prescription or over-the-counter medications, wound healing materials, and skincare ingredients. With a 16,000 square foot GMP manufacturing facility in Langhorne, PA, Alliqua provides custom hydrogels to the OEM market.
Alliqua BioMedical has made significant strides in the biomedical industry, with recent news and developments including the spin-off and merger of its Contract Manufacturing Business with TO Pharmaceuticals LLC to create an independent, publicly traded company focused on cannabinoid-based pharmaceutical therapies. Additionally, they have announced a merger agreement with Adynxx, Inc. to create a NASDAQ-listed clinical-stage pharmaceutical company with a focus on pain and inflammation. Alliqua BioMedical continues to innovate and deliver cutting-edge solutions in the field of biomedical products.
Generated from the website
